.png){kind=small}
.png){kind=small}
BackTable / Urology / Podcast / Episode #221
Perioperative Therapy for RCC: Updates & Challenges
with Dr. Sumanta Pal
Sharpen your approach to high-risk renal cell carcinoma (RCC). In this episode of BackTable Urology, guest Dr. Sumanta (Monty) Pal from City of Hope joins host Dr. Aditya Bagrodia to discuss contemporary kidney cancer treatment and the complexities of perioperative therapy.
This podcast is supported by:
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2025, March 18). Ep. 221 – Perioperative Therapy for RCC: Updates & Challenges [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Dr. Sumanta Pal
Dr. Sumantra Pal is co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team in Los Angeles, California.
Dr. Aditya Bagrodia
Dr. Aditya Bagrodia is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.
Synopsis
The conversation covers the challenging side effects of perioperative treatments, the evolution of therapies from tyrosine kinase inhibitors to modern checkpoint inhibitors, and the introduction of adjuvant therapies. Dr. Pal and Dr. Bagrodia explore the impact of these treatments on patient outcomes, the challenges with current biomarkers, and the potential of emerging trials. The doctors also highlight the importance of personalized RCC management strategies, particularly for high-risk patients and non-clear cell histologies. They also emphasize the need for appropriate patient counseling in this emerging field.
Timestamps
00:00 - Introduction
01:53 - Evolution of Kidney Cancer Treatments
03:30 - Tyrosine Kinase Inhibitors in the 2010s
10:42 - Checkpoint Inhibitor Trials
23:09 - Discussing Adjuvant Therapy with Patients
26:56 - Restaging and Biomarkers
31:58 - Challenges in Adjuvant Immunotherapy
39:57 - Non-Clear Cell RCC
41:42 - Future Directions
Resources
Photocure:
https://www.photocure.com/
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Up Next
